PMN.TO - ProMIS Neurosciences, Inc.

Toronto - Toronto Delayed Price. Currency in CAD
0.1900
0.0000 (0.00%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close0.1900
Open0.1900
Bid0.1800 x 0
Ask0.1900 x 0
Day's Range0.1850 - 0.1900
52 Week Range0.1800 - 0.4400
Volume173,487
Avg. Volume178,581
Market Cap49.667M
Beta (3Y Monthly)-2.01
PE Ratio (TTM)N/A
EPS (TTM)-0.0450
Earnings DateMar 15, 2019 - Mar 18, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est0.55
  • ProMIS Neurosciences Highlights Data for PMN310 at AAIC 2019
    PR Newswire3 days ago

    ProMIS Neurosciences Highlights Data for PMN310 at AAIC 2019

    TORONTO and CAMBRIDGE, MA, July 18, 2019 /PRNewswire/ - ProMIS Neurosciences, Inc. (PMN.TO) (ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, presented data today for its lead clinical candidate, PMN310 for Alzheimer's disease, at the annual Alzheimer's Association International Conference® (AAIC) in Los Angeles. In an oral presentation, Chief Development Officer Dr. Johanne Kaplan highlighted the therapeutic potential of PMN310 against the toxic oligomer form of amyloid beta (AßO), a root cause of Alzheimer's disease.

  • GlobeNewswire11 days ago

    ProMIS Neurosciences to Present Data at 2019 Alzheimer’s Association International Conference

    TORONTO and CAMBRIDGE, Mass., July 10, 2019 -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of.

  • ProMIS Neurosciences to Present Data at 2019 Alzheimer's Association International Conference
    CNW Group11 days ago

    ProMIS Neurosciences to Present Data at 2019 Alzheimer's Association International Conference

    ProMIS Neurosciences to Present Data at 2019 Alzheimer's Association International Conference

  • ProMIS Neurosciences' Data for Alzheimer's Disease Clinical Candidate PMN310 Published in Scientific Reports
    CNW Group12 days ago

    ProMIS Neurosciences' Data for Alzheimer's Disease Clinical Candidate PMN310 Published in Scientific Reports

    TORONTO and CAMBRIDGE, MA , July 9, 2019 /CNW/ - ProMIS Neurosciences, Inc. (PMN.TO) (ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, announced that supporting data for PMN310, its lead antibody candidate for Alzheimer's disease (AD), have been published in Scientific Reports, a journal of the Nature Research family. The open-access study is available on the Scientific Reports website using the following direct link: https://rdcu.be/bJeLB.

  • GlobeNewswire12 days ago

    ProMIS Neurosciences’ Data for Alzheimer’s Disease Clinical Candidate PMN310 Published in Scientific Reports

    TORONTO and CAMBRIDGE, Mass., July 09, 2019 -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of.

  • GlobeNewswire24 days ago

    ProMIS Neurosciences’ PMN310 Shows Greater Therapeutic Potential vs. Other Amyloid-Beta-Directed Antibodies

    ProMIS Neurosciences, Inc. (PMN.TO) (ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, presented data for its lead program, PMN310 for Alzheimer’s disease, at last week’s Keystone Symposium on Neurodegenerative Diseases. ProMIS’ Chief Development Officer Dr. Johanne Kaplan presented data showing that PMN310 possesses superior selectivity for amyloid beta toxic oligomers (AßOs) and improved therapeutic potential compared with other Aß-directed antibodies.

  • ProMIS Neurosciences' PMN310 Shows Greater Therapeutic Potential vs. Other Amyloid-Beta-Directed Antibodies
    CNW Group24 days ago

    ProMIS Neurosciences' PMN310 Shows Greater Therapeutic Potential vs. Other Amyloid-Beta-Directed Antibodies

    ProMIS Neurosciences' PMN310 Shows Greater Therapeutic Potential vs. Other Amyloid-Beta-Directed Antibodies

  • GlobeNewswire25 days ago

    ProMIS Neurosciences Closing Private Placement

    ProMIS Neurosciences, Inc. (PMN.TO) (ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, is pleased to announce that it is closing today a private placement of 4,680,000 units (the “Units”) at a price of CDN$0.25 (or US$0.1875) per Unit (the “Offering Price”) for gross proceeds of approximately CDN$1,170,000 (the “Offering”). “We are pleased with the completion of this private placement”, stated Dr. Elliot Goldstein, ProMIS President and CEO. Each Unit consists of one common share of the Company (each a “Share”) and one share purchase warrant of the Company (each a “Warrant”).

  • What Type Of Shareholder Owns ProMIS Neurosciences, Inc.'s (TSE:PMN)?
    Simply Wall St.27 days ago

    What Type Of Shareholder Owns ProMIS Neurosciences, Inc.'s (TSE:PMN)?

    A look at the shareholders of ProMIS Neurosciences, Inc. (TSE:PMN) can tell us which group is most powerful. Generally...

  • ProMIS Neurosciences Appoints Renowned Parkinson's Disease Expert Dr. C. Warren Olanow to Scientific Advisory Board
    CNW Grouplast month

    ProMIS Neurosciences Appoints Renowned Parkinson's Disease Expert Dr. C. Warren Olanow to Scientific Advisory Board

    TORONTO and CAMBRIDGE, MA , June 19, 2019 /CNW/ - ProMIS Neurosciences, Inc. (PMN.TO) (ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, welcomed Warren Olanow , MD, FRCPC, FAAN, FRCP(Hon) to its scientific advisory board (SAB). Dr. Olanow has dedicated his career to the study of neurodegeneration, particularly Parkinson's disease, through his award-winning work in academia, scientific research, clinical trials and professional societies.

  • GlobeNewswirelast month

    ProMIS Neurosciences Appoints Renowned Parkinson’s Disease Expert Dr. C. Warren Olanow to Scientific Advisory Board

    ProMIS Neurosciences, Inc. (PMN.TO) (ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, welcomed Warren Olanow, MD, FRCPC, FAAN, FRCP (Hon) to its scientific advisory board (SAB). Dr. Olanow has dedicated his career to the study of neurodegeneration, particularly Parkinson’s disease, through his award-winning work in academia, scientific research, clinical trials and professional societies.

  • Our Take On ProMIS Neurosciences, Inc.'s (TSE:PMN) CEO Salary
    Simply Wall St.last month

    Our Take On ProMIS Neurosciences, Inc.'s (TSE:PMN) CEO Salary

    Elliot Goldstein has been the CEO of ProMIS Neurosciences, Inc. (TSE:PMN) since 2015. This report will, first, examine...

  • ProMIS Neurosciences Presents Lead Program for Alzheimer's Disease at Prestigious Keystone Symposia Scientific Conference
    CNW Group2 months ago

    ProMIS Neurosciences Presents Lead Program for Alzheimer's Disease at Prestigious Keystone Symposia Scientific Conference

    TORONTO and CAMBRIDGE, MA , June 5, 2019 /CNW/ - ProMIS Neurosciences, Inc. (PMN.TO) (ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, will present key data on monoclonal antibody PMN310 for Alzheimer's disease at the Keystone Symposium on Neurodegenerative Diseases: New Insights and Therapeutic Opportunities. For nearly fifty years, the conference has attracted the world's most accomplished researchers in neurodegenerative diseases to discuss future directions in therapy and care.

  • GlobeNewswire2 months ago

    ProMIS Neurosciences Presents Lead Program for Alzheimer’s Disease at Prestigious Keystone Symposia Scientific Conference

    ProMIS Neurosciences, Inc. (PMN.TO) (ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, will present key data on monoclonal antibody PMN310 for Alzheimer’s disease at the Keystone Symposium on Neurodegenerative Diseases: New Insights and Therapeutic Opportunities. For nearly fifty years, the conference has attracted the world’s most accomplished researchers in neurodegenerative diseases to discuss future directions in therapy and care.

  • Zacks Small Cap Research2 months ago

    PMN.TO: PD & ALS Partnerships May Fund PMN310 Trial

    ProMIS Neurosciences Inc. (PMN.TO) (ARFXF) began the year acquiring new funds, announcing that the company had identified several monoclonal antibodies (mAbs) selective for α-synuclein and advancing preclinical efforts for TDP43. ProMIS’ fifth mAb program in Tau is now in the early stages of development as well.

  • PR Newswire2 months ago

    ProMIS Neurosciences' Eugene Williams to Present at JLABS' Conference on Innovations in Neurodegenerative Diseases

    TORONTO and CAMBRIDGE, MA, May 29, 2019 /PRNewswire/ - ProMIS Neurosciences, Inc. (PMN.TO) (ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, is participating in the JLABS @ Toronto conference, "Science 1st: Common Pathways and Mechanisms in Neurodegenerative Diseases" on May 30, 2019. Executive Chairman Eugene Williams will speak at the event, joining speakers from Sunnybrook Research Institute, the University of Toronto, including the Tanz Centre for Research in Neurodegenerative Diseases, Johnson and Johnson Innovations and Conference Sponsor the Ontario Brain Institute.

  • GlobeNewswire2 months ago

    ProMIS Neurosciences’ Eugene Williams to Present at JLABS’ Conference on Innovations in Neurodegenerative Diseases

    ProMIS Neurosciences, Inc. (PMN.TO) (ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, is participating in the JLABS @ Toronto conference, “Science 1st: Common Pathways and Mechanisms in Neurodegenerative Diseases” on May 30, 2019. Executive Chairman Eugene Williams will speak at the event, joining speakers from Sunnybrook Research Institute, the University of Toronto, including the Tanz Centre for Research in Neurodegenerative Diseases, Johnson and Johnson Innovations and Conference Sponsor the Ontario Brain Institute.